Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2012 Nov 5;287(52):43370–43377. doi: 10.1074/jbc.M112.408906

The Glaucoma-associated Olfactomedin Domain of Myocilin Is a Novel Calcium Binding Protein*

Rebecca K Donegan 1, Shannon E Hill 1, Katherine C Turnage 1, Susan D Orwig 1,1, Raquel L Lieberman 1,2
PMCID: PMC3527924  PMID: 23129764

Background: Myocilin is an extracellular protein linked to glaucoma but is of unknown structure and function.

Results: The myocilin olfactomedin domain contains a buried calcium ion ligated by Asp-380.

Conclusion: The myocilin olfactomedin domain binds calcium with an unprecedented ligand arrangement.

Significance: The presence of calcium within the OLF domain provides new clues into normal myocilin function, myocilin glaucoma pathogenesis, and biomedically important olfactomedin domains.

Keywords: Calcium Binding Proteins, Extracellular Matrix Proteins, Eye, Metalloproteins, Protein Misfolding, Biomechanics, Glaucoma, Olfactomedin

Abstract

Myocilin is a protein found in the trabecular meshwork extracellular matrix tissue of the eye that plays a role in regulating intraocular pressure. Both wild-type and certain myocilin variants containing mutations in the olfactomedin (OLF) domain are linked to the optic neuropathy glaucoma. Because calcium ions are important biological cofactors that play numerous roles in extracellular matrix proteins, we examined the calcium binding properties of the myocilin OLF domain (myoc-OLF). Our study reveals an unprecedented high affinity calcium binding site within myoc-OLF. The calcium ion remains bound to wild-type OLF at neutral and acidic pH. A glaucoma-causing OLF variant, myoc-OLF(D380A), is calcium-depleted. Key differences in secondary and tertiary structure between myoc-OLF(D380A) and wild-type myoc-OLF, as well as limited access to chelators, indicate that the calcium binding site is largely buried in the interior of the protein. Analysis of six conserved aspartate or glutamate residues and an additional 18 disease-causing variants revealed two other candidate residues that may be involved in calcium coordination. Our finding expands our knowledge of calcium binding in extracellular matrix proteins; provides new clues into domain structure, function, and pathogenesis for myocilin; and offers insights into highly conserved, biomedically relevant OLF domains.

Introduction

Present at millimolar concentrations, calcium ions play versatile roles in the extracellular milieu (1). Extracellular calcium ions are important in maintaining numerous cell-cell, cell-matrix, and matrix-matrix interactions, and accordingly, binding sites for calcium exist within associated extracellular matrix (ECM)3 proteins (2). Compared with our understanding of the roles of calcium in wound healing and blood coagulation, and in matrices such as bone, our comprehension of the roles of calcium in tissues of the eye is largely limited. Despite the fact that ocular hypertension accompanying the highly prevalent ocular disorder glaucoma is treated with calcium channel blockers and adrenergic receptor agonists to affect salt concentrations (3), and even though metal ions are recognized as important regulatory factors in fluid outflow through the trabecular meshwork (TM) tissue involved in maintaining intraocular pressure (4), details are still missing.

Myocilin is a unique component of the TM linked to glaucoma pathogenesis. First, myocilin is associated with steroid-induced, secondary forms of glaucoma. Steroid treatment increases myocilin expression (5), and high levels of myocilin have been shown to activate the unfolded protein response in Drosophila eyes (6), but the pathogenic mechanism has not yet been elucidated (7). Second, mutations in myocilin comprise the strongest genetic linkage to primary open angle glaucoma, the most prevalent disease subtype. Inherited in an autosomal-dominant fashion, non-synonymous mutations in myocilin, which are localized to its enigmatic olfactomedin (myoc-OLF) domain, result in the accumulation of myocilin within human TM cells instead of secretion to the TM (8). The scenario presents a toxic gain of function wherein TM cells expressing mutant myocilin die and, by an unknown mechanism, lead to an increase in intraocular pressure, which brings about the early onset of glaucoma symptoms. Overall, myocilin-associated inherited glaucoma falls into a protein conformational disorder; mutant myocilin aggregation may be a function of the fact that disease-causing myoc-OLF variants are less stable than their wild-type counterpart (9) and/or their ability to form amyloid fibrils (10).

Paradoxically, despite its clear disease relevance, little is known about the structure or normal biological function of myocilin in the TM. In studies of full-length myocilin, extracellular matrix interacting partners such as actin, laminin, fibronectin, and heparan sulfate, as well as cell-matrix adhesion properties, have been localized to the N-terminal coiled-coil, not the OLF domain (1115). In addition, the explicit functions of non-myocilin OLF homologs, distributed throughout the body and commonly found in neural tissues, are also unknown (16). Other than myocilin, there has been limited functional and molecular characterization of other OLF-containing proteins, such as amassin-1, a sea urchin protein involved in cell-cell adhesion of coelomocytes (17), gliomedin involved in nerve conduction within myelinating fibers (18), and olfactomedin-4, which has recently emerged as a factor in a variety of human disorders, including some cancers (1921) and irritable bowel syndrome (22).

Based on the high calcium levels measured in ocular fluid (23, 24), similar to other ECM environments (25), we set out to investigate whether the OLF domain of myocilin harbors a calcium binding site. The presence of numerous highly conserved aspartates among OLF domains (Fig. 1) and interaction of myocilin with negatively charged glycosaminoglycans (14) further suggest a need for such charge stabilization. Although sequence gazing and bioinformatics approaches failed to identify any canonical calcium binding motifs, we experimentally identified and characterized an unprecedented, single, high affinity, calcium binding site within the OLF domain of myocilin. This site is likely prevalent among OLF domains. Our results suggest new roles for myocilin in the TM and possible contribution to the pathogenesis of glaucoma.

FIGURE 1.

FIGURE 1.

PROMALS (30) sequence alignment of the OLF domain of myocilins from human (gi_3065674), zebrafish (gi_62632725), cow (gi_74356501), pig (gi_47522798), mouse (gi_15077142), and rat (gi_3845607), as well as (non-myocilin) amassin (gi_28453877) from sea urchin. Consensus secondary structure (SS) is depicted above the alignment. e, β-strand; h, helix. Asterisk indicates location of glaucoma-causing mutations examined in this study. Red residues are identical; blue residues are similar. Highlighted residues are conserved aspartate/glutamate positions subjected to site-directed mutagenesis in this study.

EXPERIMENTAL PROCEDURES

Expression and Purification

myoc-OLF and variants were expressed using a modified pMAL-c4x plasmid encoding an N-terminal maltose binding protein (MBP) fusion (New England Biolabs) in Rosetta Gami 2 (DE3)pLysS (Novagen) cells, as described previously (26). Cells were grown at 37 °C in Superior Broth (US Biological) to an optical density at 600 nm of 0.6–0.8, cooled to 18 °C, induced with 0.5 mm isopropyl β-d-thiogalactopyranoside and allowed to grow overnight (14–16 h). Cells were flash frozen with liquid nitrogen and stored at −80 °C. Cell pellets were lysed via French Press after suspension in amylose wash buffer (10 mm KH2PO4, 10 mm Na2HPO4, 200 mm NaCl, and 1 mm EDTA) containing Roche Complete EDTA-free Protease Inhibitor Mixture. Cellular debris was removed via ultracentrifugation (162,000 × g for 45 min at 4 °C), and the supernatant was loaded onto a 20-ml column containing high flow amylose resin (New England Biolabs) equilibrated with amylose wash buffer. The MBP-OLF fusion protein was eluted using amylose wash buffer supplemented with 10 mm maltose. Elution fractions were concentrated using Amicon Ultra-15 centrifugal filtration devices and loaded onto a Superdex 75 prep grade column (GE Healthcare) equilibrated with gel filtration buffer (10 mm KH2PO4, 10 mm Na2HPO4, and 200 mm NaCl, pH 6.8). Fractions of MBP-OLF monomer were identified by SDS-PAGE analysis, pooled, and concentrated for further use or for protease cleavage. Cleavage of MBP-OLF was accomplished using Factor Xa (New England Biolabs or Roche Applied Science) incubated for 16–18 h in 50 mm Tris, pH 8, 100 mm NaCl, and 5 mm CaCl2 at 37 °C (wild-type) or room temperature (variants). Cleaved protein was loaded onto the amylose resin column to remove MBP and uncleaved fusion protein. Flow-through fractions containing cleaved myoc-OLF and Factor Xa were concentrated and subjected to fractionation by Superdex 75 size exclusion column chromatography. Fractions containing cleaved, pure, myoc-OLF were identified by SDS-PAGE, pooled, and concentrated for further use.

Generation of myoc-OLF Variants

Site-directed mutagenesis was accomplished using the QuikChange II® site-directed mutagenesis kit (Stratagene). Primers were designed using PrimerX and synthesized by MWG Operon (sequences not published previously (9, 26) appear in supplemental Table S1). All mutated plasmid sequences were confirmed by DNA sequencing (MWG Operon). Protein expression and purification proceeded as above. The structural core of myoc-OLF (core-OLF), which lacks Asp-490, was generated by limited proteolysis as described previously (27).

Thermal Stability Assay

Changes in thermal stability were assessed by differential scanning fluorimetry (28), as modified by us previously for MBP-OLF (26, 27). Briefly, 30-μl reactions containing final concentrations of 1–3 μm myoc-OLF or MBP-OLF variants were diluted into buffer containing 10 mm Hepes, pH 7.5, 200 mm NaCl, and 5× Sypro Orange dye (Invitrogen). For MBP-OLF variants, 50 mm maltose was added to stabilize MBP well beyond the range of OLF (26). Salts (CaCl2, Ca(OAc)2, MgCl2, or Mg(OAc)2) were added in the range of 0–25 mm. The mixtures were dispensed into 96-well optical plates and sealed with optical film (Applied Biosystems). Sypro Orange fluorescence was monitored as a function of temperature in an Applied Biosystems Step One Plus RT-PCR with fixed excitation at 480 nm and a ROX 610 nm emission filter. Thermal melts were conducted in triplicate on two independent samples from 25 to 95 °C (5–95 °C for myoc-OLF(D273A) and myoc-OLF(Y437H)) with 1 °C/min incremental increase. Fluorescence data were blank-subtracted, and Boltzmann Sigmoid analysis conducted using GraphPad Prism to determine the midway point of unfolding, i.e. the melting temperature (Tm).

Fluorescence Ca2+ Binding Assay

Purified proteins were concentrated and rediluted three times into 10 mm Hepes, pH 7.5, using aforementioned centrifugal filtration devices. The fluorescence of the nanomolar affinity Ca2+ chelator Quin-2 (29) was then measured under native and denaturing conditions.4 Reactions containing 8 μm myoc-OLF or myoc-OLF(D380A), 150 μm Quin-2, and either 0 or 1.4 m GndHCl in 10 mm Hepes, pH 7.5 buffer were added to Bio-One Fluotrac 200 (Grenier) 96 half-well plates. Fluorescence emission was measured on a Biotek Synergy 2 plate reader (excitation, 360/40 nm; emission, 528/20 nm). At least two independent measurements were conducted for each sample. Reported fluorescence values are blank-subtracted.

Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES)

As-isolated MBP-OLF was prepared for ICP-OES as described above. Samples of EDTA-free MBP-OLF, MBP-OLF(D380A), and MBP were purified as reported except EDTA was omitted from amylose wash buffer, and gel filtration buffer was chelated with Chelex (Sigma) resin. Duplicate independent samples of 74–95 μm protein and buffer blanks were analyzed for Ca2+ content (University of Georgia Center for Applied Isotope Studies). Data were blank-subtracted, molar ratios were calculated, and averages were reported. Protein concentrations for MBP-OLF and MBP-OLF(D380A) were based on the experimental molar extinction coefficient at 280 nm of 169,978 m−1 cm−1 obtained from total amino acid analysis (University of California, Davis Molecular Structure Facility).

Circular Dichroism (CD)

Far-UV CD, near-UV CD, and CD thermal melts were acquired on a Jasco J-810 or J-815 spectropolarimeter equipped with Neslab RTE 111 circulating water bath and a Jasco PTC-4245/15 temperature control system. For far-UV spectra, samples examined were myoc-OLF and myoc-OLF(D380A) in gel filtration buffer, pH 7.2. For myoc-OLF at pH 4.6, purified protein was subjected to 3× concentration and dilution into 10 mm sodium acetate, 200 mm NaCl, pH 4.6, using an Amicon Ultra 15 centrifugal device. For thermal melts, protein samples were first diluted into 10 mm MES, pH 6.0, buffer and supplemented with 0 or 1 mm CaCl2 to a final concentration of 10–12 μm. No differences in secondary structure were observed between samples prepared in pH 6.0 or 7.2 (data not shown). Far-UV spectra were acquired at 4 or 20 °C with 30 averaged scans from 300 to 200 nm at a 500 nm min−1 scan rate, using a 0.1-cm cuvette. Far-UV melts were performed in duplicate utilizing a 1 °C min−1 increase in temperature from 5 to 95 °C. Ten scans from 300 to 200 nm at a 500-nm min−1 scan rate were averaged for each temperature. Data were blank-subtracted and converted to mean residue ellipticity ϴ = Mres × ϴobs/10 × d × c, where Mres = 112.9 is the mean residue mass calculated from the protein sequence; ϴobs is the observed ellipticity (degrees) at wavelength λ; d is the path length (cm); and c is the protein concentration (g/ml). The Tm was determined using mean residue ellipticity values recorded at 215 nm via Boltzmann Sigmoid analysis using Igor Pro.

Near-UV CD experiments were conducted with myoc-OLF at pH 7.2, at pH 4.6, and myoc-OLF(D380A) at pH 7.2 (40–50 μm protein concentration) prepared as described above. Scans were measured from 250 nm to 320 nm at a rate of 50 nm/min and a data pitch of 1 nm using a 0.1-cm cuvette. Each measurement was an average of 10 scans, converted to mean residue ellipticity.

Estimate of Ca2+ Dissociation Constant (Kd)

The Kd of Ca2+ for myoc-OLF was estimated with the binding constant macro in Origin (version 7) using data from differential scanning calorimetry (MicroCal VP-Capillary DSC) conducted at 15.4 μm protein concentration in gel filtration buffer. The unfolding transitions for both myoc-OLF and myoc-OLF(D380A) are not reversible but can be fit well to a non-two-state model (data not shown). Data from myoc-OLF(D380A) were used as an approximation for apo myoc-OLF (see “Results”). Relevant parameters: For myoc-OLF Tm = 56.3 °C, and for myoc-OLF(D380A), Tm = 51.5 °C, ΔHcal = 8.22 × 104 kcal/mol, ΔCp = 1450 cal/deg·mol.

RESULTS

Initial Identification of Ca2+ in myoc-OLF

We previously examined the effects of metal ions on the stability of myoc-OLF, but aspects of experimental design excluded calcium ions (27). Reassessment of myoc-OLF stability with calcium ions in a compatible buffer revealed a clear, anion-independent increase in thermal stability, as measured by differential scanning fluorimetry (Table 1; see “Experimental Procedures”), a technique that reports ligand binding as an increase in thermal stability (28). This phenomenon is observed even in the case of a fully bound protein when the ligand only binds the folded state of the protein (31).

TABLE 1.

Analysis of stabilization of myoc-OLF by divalent metal ions

Sample Tm ΔTm
°C °C
Myoc-OLF 53.0 ± 0.5
Myoc-OLF + 10 mm CaCl2 59.6 ± 0.2 6.6
Myoc-OLF + 10 mm Ca(OAc)2 60.0 ± 0.1 7.0
Myoc-OLF + 10 mm MgCl2 52.8 ± 0.2 −0.2
Myoc-OLF + 10 mm Mg(OAc)2 53.6 ± 0.5 0.6
Myoc-OLF, pH 4.6 48.9 ± 0.1
Myoc-OLF, pH 4.6 + 10 mm CaCl2 53.6 ± 0.1 4.7

Given the fact that the typical purification procedure involves numerous hours of contact with buffers containing 1 mm EDTA (Kd = 3.2 × 10−8 m for Ca2+ (32)), we expected the as-isolated MBP-OLF fusion protein to lack Ca2+. However, elemental analysis by ICP-OES (Table 2) revealed significant levels of Ca2+. Omission of EDTA from the purification procedure yielded nearly stoichiometric values consistent with a singly bound Ca2+ ion to the monomeric MBP-OLF; Ca2+ does not copurify with MBP (Table 2). When incubated with Quin-2, a fluorescent EGTA analog with Kd = 2.9 × 10−9 m (29), high fluorescence values indicative of Ca2+ release from myoc-OLF were only detected under denaturing conditions (Fig. 2). To date, we have not been able to prepare a native form of apo myoc-OLF or fully reload myoc-OLF. Isothermal titration calorimetry using myoc-OLF reveals only nonspecific binding; no additional binding sites are apparent (supplemental Fig. S1).

TABLE 2.

Elemental analysis for Ca2+ by ICP-OES

Sample Calcium:protein (per mol)
MBP-OLF as-isolated 0.81
EDTA-free MBP-OLF 0.96
MBP-OLF(D380A) 0.10
MBP 0.01
FIGURE 2.

FIGURE 2.

Ca2+ binding assay for myoc-OLF and myoc-OLF(D380A). Fluorescence (in a.f.u., arbitrary fluorescence units) of chelator Quin-2 due to Ca2+ binding is measured under native and denaturing conditions.

Mutational Analysis of Carboxylic Acid-containing Residues as Ligands for Ca2+ Reveals Asp-273 and Glaucoma-associated Asp-380

To deduce the metal binding residues in myoc-OLF, and in light of the fact that there is no enzymatic activity reported for myocilin, we tested site-directed myoc-OLF mutants for stabilization by Ca2+. A variant that loses its ability to be stabilized by calcium is lacking a candidate ligand. A total of six candidate conserved aspartates or glutamates, side chains commonly found as ligands to calcium ions in proteins (33), were identified by sequence analysis of the myocilin OLF domains from other organisms (Fig. 1). Of these, Asp-273, Asp-378, Asp-384, and Glu-385 were replaced with alanine specifically for this study. Asp-380 was previously mutated to alanine and is also a disease-causing variant (26); the sixth, Asp-490, is removed when generating core OLF (27). Myoc-OLF(D378A) could only be isolated in an aggregated state, and thus, stability measurements on the folded monomer could not be conducted. The challenge encountered with myoc-OLF(D378A) is somewhat surprising given that the equivalent position in the non-myocilin, OLF domain of the ortholog amassin is an alanine (Fig. 1, gi_28453877).

Both myoc-OLF(D273A) and myoc-OLF(D380A) were isolated as monomers in sufficient quantities, and their stabilities were found to be unaffected by the presence of Ca2+. Thus, both Asp-380 and Asp-273 are candidate ligands for Ca2+ in myoc-OLF. Due to the low initial stability of the D273A variant (Tm ∼ 22 °C), however, we only cautiously assign Asp-273 as a ligand. By contrast, the D380A variant, is a moderately stable protein (Tm ∼ 46 °C) and was evaluated further (see below). In addition to completely ablating stabilization by Ca2+, myoc-OLF(D380A) does not co-purify with Ca2+, as confirmed by Quin-2 binding (Fig. 2) and metal analysis (Table 2).

Structural Differences between Apo myoc-OLF(D380A) and Wild-type myoc-OLF

We next examined structural differences between apo and holo myoc-OLF by comparing CD spectra of wild-type myoc-OLF at pH 7.2 and 4.6 and myoc-OLF(D380A) at pH 7.2 (Fig. 3, A and B). The secondary structure spectra overlay well, with features of β-sheets at ∼215 nm and an unusual signal at 232 nm seen by us previously (26, 27). This latter feature is more pronounced in myoc-OLF(D380A) compared with myoc-OLF at pH 7.2 but is similar to wild-type OLF at pH 4.6 (Fig. 3A) (27). Literature precedents suggest the 232 nm signal could be a β-turn (34) and/or exposed tryptophan residue (35). In support of the latter interpretation for myoc-OLF, the tertiary structure observed in the aromatic region of myoc-OLF(D380A) is somewhat different from wild-type at pH 7.2. However, the spectrum overlays with wild-type myoc-OLF at pH 4.6 (Fig. 3B). Because myoc-OLF at pH 4.6 is a well folded (27), Ca2+-stabilized protein (Table 1), the structural changes in myoc-OLF(D380A) that lead to ablation of Ca2+ binding are due to the loss of coordination of Asp-380 to Ca2+ and not a change in the structure of myoc-OLF or the Ca2+ binding pocket.

FIGURE 3.

FIGURE 3.

Structural and stability comparison of myoc-OLF and myoc-OLF(D380A). Shown is a comparison of secondary structure from far-UV spectra (a) and tertiary structure from near-UV spectra (b) among wild-type myoc-OLF at pH 7.2, wild-type myoc-OLF at pH 4.6, and myoc-OLF(D380A) at pH 7.2. c, CD thermal melts for myoc-OLF and myoc-OLF(D380A) in MES pH 6.0, monitored at 215 nm in the presence and absence of exogenous Ca2+.

Investigation of Ca2+ Stabilization of 18 Other Disease-causing myoc-OLF Variants Reveals No Other Impaired Variants

Due to the documented participation of other polar residues or main chain-derived carbonyls in Ca2+ binding (33), combined with the glaucoma relevance of myoc-OLF(D380A), we looked at the extent of stabilization by Ca2+ for 18 disease-causing OLF mutants (Table 3). With the exception of D380A, all of the disease-causing variants were stabilized by +5.7–9.1 °C in the presence of 10 mm Ca2+; wild-type myoc-OLF is stabilized by 6.5 °C. Although the extent of stabilization varies somewhat, lack of calcium binding is not a general feature of disease-causing variants, and we were not able to statistically correlate initial Tm or position in the amino acid sequence with extent of stabilization. Thus, the remaining cryptic Ca2+ coordination sphere likely involves some combination of other side chains not yet identified, main chain carbonyls, or water molecules.

TABLE 3.

Analysis of stabilization of OLF variants by Ca2+

Variant Rationale Tm Tm + 10 mm CaCl2 ΔTm
°C °C °C
myoc-OLF Wild-type 53.0 ± 0.5 59.6 ± 0.2 6.6
myoc-OLF core Identified structural corea 49.7 ± 0.3 57.7 ± 0.1 8.1
MBP-OLF(G246R) Disease-causing variant 42.5 ± 0.2 50.6 ± 0.0 8.1
MBP-OLF(G252R) Disease-causing variant 43.0 ± 0.2 51.5 ± 0.2 8.5
MBP-OLF(R272G) Disease-causing variant 41.0 ± 0.3 48.6 ± 0.1 7.6
MBP-OLF(D273A) Carboxylate side chain? 21.7 ± 0.8 21.1 ± 0.7 −0.6
MBP-OLF(E323K) Disease-causing variant 44.0 ± 0.5 50.3 ± 0.2 6.2
MBP-OLF(G364V) Disease-causing variant 45.0 ± 0.4 51.9 ± 0.1 6.9
MBP-OLF(G367R) Disease-causing variant 42.7 ± 0.1 50.9 ± 0.4 8.1
MBP-OLF(T377M) Disease-causing variant 44.3 ± 0.3 50.6 ± 0.6 6.3
MBP-OLF(D378A) Carboxylate side chain? N/A N/A N/Ab
MBP-OLF(D380A) Carboxylate side chain ligand? and disease causing variant 46.6 ± 0.3 45.1 ± 0.5 −1.5
MBP-OLF(D384A) Carboxylate side chain ligand? 42.5 ± 0.7 53.6 ± 0.5 11.1
MBP-OLF(E385A) Carboxylate side chain ligand? 39.7 ± 0.4 49.7 ± 0.3 10
MBP-OLF(K423E) Disease-causing variant 34.2 ± 0.4 43.2 ± 0.1 9.0
MBP-OLF(V426F) Disease-causing variant 41.5 ± 0.1 49.9 ± 0.1 8.4
MBP-OLF(A427T) Disease-causing variant 48.3 ± 0.3 55.2 ± 0.4 6.9
MBP-OLF(C433R) disease causing variant 40.4 ± 0.4 49.4 ± 0.5 9.0
MBP-OLF(Y437H) Disease-causing variant 40.3 ± 0.4 48.6 ± 0.2 8.3
MBP-OLF(I477N) Disease-causing variant 37.7 ± 0.8 46.8 ± 0.2 9.1
MBP-OLF(I477S) Disease-causing variant 39.7 ± 0.2 48.2 ± 0.5 8.5
MBP-OLF(N480K) Disease-causing variant 42.4 ± 0.2 48.1 ± 0.1 5.9
MBP-OLF(P481L) Disease-causing variant 45.5 ± 0.4 51.2 ± 0.3 5.7
MBP-OLF(I499F) Disease-causing variant 42.8 ± 0.1 50.4 ± 0.4 7.6
MBP-OLF(S502P) Disease-causing variant 41.0 ± 0.3 49.9 ± 0.2 8.9

a From Ref. 27.

b Variant could not be purified in sufficient quantities in folded state for measurement.

Estimation of Ca2+ Dissociation Constant

Because a strictly apo wild-type myoc-OLF protein could not be prepared for direct calorimetric measurement of calcium binding, we estimated the dissociation constant from experimental Tm values obtained by differential scanning calorimetry, which are corroborated by CD (Fig. 3C) and differential scanning fluorimetry (Table 3), as well as experimental values for the enthalpy of unfolding and change in heat capacity for myoc-OLF(D380A)5 as a proxy for apo myoc-OLF. These values lead to a calculated Kd ∼ 1.3 × 10−6 m for Ca2+ in myoc-OLF. Combined with results from near-UV CD and inaccessibility to chelators under native conditions, we infer that the myoc-OLF Ca2+ binding site has limited solvent accessibility.

Model for Ca2+ Binding Motif in myoc-OLF

On the basis of bioinformatics approaches, neither the popular D(D/N)DG sequence found among integrins, EF-hands, and β-blades (36, 37) nor the EGF-like motif DXD(Q/E)X14(D/N) (38), is present in myoc-OLF. Thus, to gain additional structural insight, we probed the region of the myoc-OLF sequence containing Asp-380 (378–393) using HH-PRED (39) and Robetta (40), revealing as expected from CD, a high β-strand propensity. Although no structurally similar Ca2+ binding proteins were identified by HH-PRED, the Mg2+-dependent d-alanine d-alanine ligase (Protein Data Bank code 1IOW) and a Zn2+-dependent Haemophilus influenzae enzyme (Protein Data Bank code 1NO5) use a β-strand-embedded aspartate at a position equivalent to Asp-380 for metal ion binding. Thus, even though calcium binding sites are generally found within a loop region, the site in myoc-OLF may instead resemble one of these other metalloproteins. Notably, the sequence Gly-387–Tyr-392, which forms a predicted β-strand separate from that containing Asp-380, bears resemblance to the C-terminal region of γS-crystallin (Protein Data Bank code 1HA4), the cataract-associated lens protein. Although an equivalent aspartate to Asp-380 is not present in γS-crystallin, the βγ-crystallin superfamily does bind calcium (41) using consensus sequence (N/D)(N/D)XnI(S/T)S (42), which is also absent in myoc-OLF.

Prediction of Ca2+ Binding Motifs in the OLF Domain Family

Finally, we broadened our scope beyond myocilin to include other OLF domain containing proteins to gain insight into whether calcium binding may be an inherent characteristic of such domains. Among myocilin orthologs, Asp-380 is located in a well conserved region of the OLF domain peppered with acidic residues that were subjected to mutagenesis in our study (see above). Expansion of sequence analysis to include 45 OLF homologs available in ProSite (43), combined with an evolutionary trace (44), reveals that all but one distant branch harbors an aspartate or glutamate at the equivalent position of 380 in myocilin (supplemental Fig. S2). Instead of aspartate, these distant relatives, the gliomedins, harbor asparagine, which is unlikely to be a ligand for calcium. Asp-273 is also highly conserved among the expanded list of OLF domains, with the only outliers in the same branch lacking a Asp-380. Asp-378 is far less conserved, being replaced with tyrosine, leucine, and phenylalanine. Thus, although many variants appear to have a well positioned aspartate for calcium binding, additional characterization of other OLF domains will be required to assess further generality.

DISCUSSION

We have identified a novel, high affinity Ca2+ site within the OLF domain of myocilin. The myoc-OLF Ca2+ binding site contains an unprecedented motif that includes Asp-380, also the site of a glaucoma-causing lesion. Of the 23 total myoc-OLF variants we investigated, including mutants of conserved aspartate/glutamate residues, as well as disease-causing mutants, only two additional candidate ligands emerged, namely, Asp-273 and Asp-378. However, neither position could be confirmed unambiguously due to the severely impaired biophysical properties of the resulting recombinant protein. The combination of low thermal stability of myoc-OLF(D273A) and its high level of conservation among orthologs at this position underscores the importance of this residue to the integrity of the OLF domain. This stability reduction is highly residue-specific; myoc-OLF(R272G), the adjacent disease variant, is a moderately stable protein that is stabilized by calcium. By comparison, although Asp-378 could hypothetically form part of the prevalent DXD Ca2+ binding loop found in EF-hands and β-blades, the remaining motif is absent, Asp-378 is not well conserved among OLF domains, and Asp-380 is predicted to be located within a β-strand, not a loop. The varied nature of calcium binding sites in proteins, which include not only oxygen-containing amino acid side chains but also main chain carbonyls, hydroxyl moieties, and water molecules for a total coordination number of 6–8 (45), may render the remaining Ca2+ coordination environment in myoc-OLF inaccessible by site-directed mutagenesis. At present, however, there is no OLF structure or high-confidence homology model for further insight.

Two of the major proposed functions of Ca2+ binding sites in ECM proteins are the enhancement of thermal stability and protection against proteolysis (25). In support of these roles, we previously observed resistance of myoc-OLF to protease treatment (27) and core-OLF is still stabilized by calcium. Unlike other known calcium-containing ECM proteins like osteonectin, in which the binding of calcium induces a large conformational change (46), wild-type myoc-OLF at pH 7.2, myoc-OLF at pH 4.6, and myoc-OLF(D380A) are stable proteins with highly similar structural features. Thus, although myoc-OLF at pH 7.2 is more stable than the D380A mutant to thermal denaturation, calcium is not absolutely required for OLF folding.

The estimated binding affinity of the myoc-OLF calcium site based on available thermodynamic parameters is also in line with Ca2+ equilibrium dissociation constants of other ECM proteins, which are usually in the micromolar range (2). However, myocilin is atypical in that the site is largely inaccessible to the strong chelators EDTA and Quin-2. This indicates that metallation likely occurs upon folding in the calcium-rich endoplasmic reticulum (47). Based on experimental measurements of millimolar levels of calcium ions in aqueous humor (23, 24), the myocilin OLF domain should be continually saturated with Ca2+ once trafficked to the TM.

In addition to conferring stability, Ca2+ sites in ECM proteins play regulatory or signaling roles, for example, in response to local calcium ion gradients (2). The emerging picture appears true in proteins with a stabilizing, high affinity Ca2+ site, regardless of whether Ca2+ is bound within a single protein domain or at the interface between domains. Calcium ions may directly facilitate ligand interaction or membrane association, or stabilize a particular protein conformation so that it is primed for ligand binding or activated for catalysis (1). Full-length myocilin is a modular protein like other ECM proteins, but myocilin is unusual in that it has a coiled-coil for oligomerization instead of a repeated domain structure within a single polypeptide chain. The OLF domain behaves as a monomer in vitro (26, 27), and it has been suggested that the myocilin domain structure brings OLF domains in close proximity, albeit in an unknown configuration and for an unclear purpose. Even though all but one (48) of the interacting partners for myocilin identified to date appear to not require the OLF domain, our results hint at the possibility that these and other interactions may be calcium-dependent or require a transient calcium gradient. In support of this hypothesis, in the case of amassin, cell-cell interactions were found to be contingent upon the presence of calcium ions (49).

Although currently there is no experimental evidence for calcium involvement in biomechanical stress response in the TM, it is well known that calcium is associated with muscle contraction, cell shape, and adhesion, by altering myosin interaction with actin (50). Relevant to the myocilin system, mechanical stress of TM cells leads to rearrangements of actin filaments (51) and elevated levels of myocilin mRNA (52). Myocilin has also been proposed to interact directly with actin via its coiled-coil (15). This syllogism suggests that myocilin could be sensitive to shear and/or other biomechanical stress via a calcium-dependent mechanism. Alternatively, myocilin may play a part in the regulation of TM calcification. Genes associated with calcification are abundantly expressed in the TM. Although the details of calcification and/or prevention in the TM and their physiological or pathological role(s) are still unknown (53), myocilin mutants can alter the expression of calcification genes (54), suggesting interplay is possible.

In sum, the new knowledge of a calcium site in myoc-OLF opens a completely new context in which to probe the biological and pathogenic roles of myocilin. Additional characterization of the OLF domain in the context of full-length myocilin, calcium fluxes, and mechanical stress in the TM should both yield new functional insights for myocilin and contribute to our still poor comprehension of the role of Ca2+ in the anterior segment of the eye.

Acknowledgments

We thank Dana Freeman for assistance in cell growth and Anton Petrov, Chad Bernier, and C. Ross Ethier for helpful discussions.

*

This work was supported in part by National Institutes of Health Grant R01EY021205 (to R. L. L.).

4

S. D. Orwig, P. V. Chi, Y. Du, S. E. Hill, K. C. Turnage, H. Fu, and R. L. Lieberman, submitted for publication.

5

K. C. Turnage and R. L. Lieberman, manuscript in preparation.

3
The abbreviations used are:
ECM
extracellular matrix
OLF
olfactomedin
myoc-OLF
myocilin OLF domain
TM
trabecular meshwork
MBP
maltose binding protein
ICP-OES
inductively coupled plasma-optical emission spectroscopy.

REFERENCES

  • 1. Evenäs J., Malmendal A., Forsén S. (1998) Calcium. Curr. Opin. Chem. Biol. 2, 293–302 [DOI] [PubMed] [Google Scholar]
  • 2. Maurer P., Hohenester E. (1997) Structural and functional aspects of calcium binding in extracellular matrix proteins. Matrix Biol. 15, 569–580 [DOI] [PubMed] [Google Scholar]
  • 3. Zhang K., Zhang L., Weinreb R. N. (2012) Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat. Rev. Drug Discov. 11, 541–559 [DOI] [PubMed] [Google Scholar]
  • 4. McLaughlin C. W., Karl M. O., Zellhuber-McMillan S., Wang Z., Do C. W., Leung C. T., Li A., Stone R. A., Macknight A. D., Civan M. M. (2008) Electron probe X-ray microanalysis of intact pathway for human aqueous humor outflow. Am. J. Physiol. Cell Physiol. 295, C1083–1091 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Polansky J. R., Fauss D. J., Chen P., Chen H., Lütjen-Drecoll E., Johnson D., Kurtz R. M., Ma Z. D., Bloom E., Nguyen T. D. (1997) Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica 211, 126–139 [DOI] [PubMed] [Google Scholar]
  • 6. Carbone M. A., Ayroles J. F., Yamamoto A., Morozova T. V., West S. A., Magwire M. M., Mackay T. F., Anholt R. R. (2009) Overexpression of myocilin in the Drosophila eye activates the unfolded protein response: implications for glaucoma. PLoS One 4, e4216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Clark A. F., Wordinger R. J. (2009) The role of steroids in outflow resistance. Exp. Eye Res. 88, 752–759 [DOI] [PubMed] [Google Scholar]
  • 8. Resch Z. T., Fautsch M. P. (2009) Glaucoma-associated myocilin: a better understanding but much more to learn. Exp. Eye Res. 88, 704–712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Burns J. N., Turnage K. C., Walker C. A., Lieberman R. L. (2011) The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder. Biochemistry 50, 5824–5833 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Orwig S. D., Perry C. W., Kim L. Y., Turnage K. C., Zhang R., Vollrath D., Schmidt-Krey I., Lieberman R. L. (2012) Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin. J. Mol. Biol. 421, 242–255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Fautsch M. P., Johnson D. H. (2001) Characterization of myocilin-myocilin interactions. Invest. Ophthalmol. Vis. Sci. 42, 2324–2331 [PubMed] [Google Scholar]
  • 12. Fautsch M. P., Vrabel A. M., Johnson D. H. (2006) The identification of myocilin-associated proteins in the human trabecular meshwork. Exp. Eye Res. 82, 1046–1052 [DOI] [PubMed] [Google Scholar]
  • 13. Goldwich A., Scholz M., Tamm E. R. (2009) Myocilin promotes substrate adhesion, spreading and formation of focal contacts in podocytes and mesangial cells. Histochem. Cell Biol. 131, 167–180 [DOI] [PubMed] [Google Scholar]
  • 14. Peters D. M., Herbert K., Biddick B., Peterson J. A. (2005) Myocilin binding to Hep II domain of fibronectin inhibits cell spreading and incorporation of paxillin into focal adhesions. Exp. Cell Res. 303, 218–228 [DOI] [PubMed] [Google Scholar]
  • 15. Wentz-Hunter K., Ueda J., Yue B. Y. (2002) Protein interactions with myocilin. Invest. Ophthalmol. Vis. Sci. 43, 176–182 [PubMed] [Google Scholar]
  • 16. Tomarev S. I., Nakaya N. (2009) Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology. Mol. Neurobiol. 40, 122–138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Hillier B. J., Vacquier V. D. (2007) Structural features and functional domains of amassin-1, a cell-binding olfactomedin protein. Biochem. Cell Biol. 85, 552–562 [DOI] [PubMed] [Google Scholar]
  • 18. Labasque M., Devaux J. J., Lévêque C., Faivre-Sarrailh C. (2011) Fibronectin type III-like domains of neurofascin-186 protein mediate gliomedin binding and its clustering at the developing nodes of Ranvier. J. Biol. Chem. 286, 42426–42434 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Yu L., Wang L., Chen S. (2011) Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers. Neoplasma 58, 9–13 [DOI] [PubMed] [Google Scholar]
  • 20. Kobayashi D., Koshida S., Moriai R., Tsuji N., Watanabe N. (2007) Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci. 98, 334–340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Liu R. H., Yang M. H., Xiang H., Bao L. M., Yang H. A., Yue L. W., Jiang X., Ang N., Wu L. Y., Huang Y. (2012) Depletion of OLFM4 gene inhibits cell growth and increases sensitization to hydrogen peroxide and tumor necrosis factor-α induced apoptosis in gastric cancer cells. J. Biomed. Sci. 19, 38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Gersemann M., Becker S., Nuding S., Antoni L., Ott G., Fritz P., Oue N., Yasui W., Wehkamp J., Stange E. F. (2012) Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD. J. Crohns Colitis 6, 425–434 [DOI] [PubMed] [Google Scholar]
  • 23. Cruciani F., Moramarco A., Antonelli B., Mollo R., Balacco-Gabrieli C., Costantini S., Ciaralli L., Giordano R., Sepe A., Damore E., Valeri M. (2004) Evaluation of five elements in lenses and aqueous humour of experimental rabbits after induced opacity. J. Trace Elem. Med. Biol. 18, 141–147 [DOI] [PubMed] [Google Scholar]
  • 24. Ringvold A., Sagen E., Bjerve K. S., Folling I. (1988) The calcium and magnesium content of the human lens and aqueous humor. A study in patients with hypocalcemic and senile cataract. Acta Ophthalmol. (Copenh). 66, 153–156 [DOI] [PubMed] [Google Scholar]
  • 25. Maurer P., Hohenester E., Engel J. (1996) Extracellular calcium-binding proteins. Curr. Opin. Cell Biol. 8, 609–617 [DOI] [PubMed] [Google Scholar]
  • 26. Burns J. N., Orwig S. D., Harris J. L., Watkins J. D., Vollrath D., Lieberman R. L. (2010) Rescue of glaucoma-causing mutant myocilin thermal stability by chemical chaperones. ACS Chem. Biol. 5, 477–487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Orwig S. D., Lieberman R. L. (2011) Biophysical characterization of the olfactomedin domain of myocilin, an extracellular matrix protein implicated in inherited forms of glaucoma. PLoS One 6, e16347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Niesen F. H., Berglund H., Vedadi M. (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212–2221 [DOI] [PubMed] [Google Scholar]
  • 29. Bryant D. T. (1985) Quin 2: the dissociation constants of its Ca2+ and Mg2+ complexes and its use in a fluorimetric method for determining the dissociation of Ca2+-protein complexes. Biochem. J. 226, 613–616 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Pei J., Grishin N. V. (2007) PROMALS: towards accurate multiple sequence alignments of distantly related proteins. Bioinformatics 23, 802–808 [DOI] [PubMed] [Google Scholar]
  • 31. Sanchez-Ruiz J. M. (2007) Ligand effects on protein thermodynamic stability. Biophys. Chem. 126, 43–49 [DOI] [PubMed] [Google Scholar]
  • 32. Smith P. D., Liesegang G. W., Berger R. L., Czerlinski G., Podolsky R. J. (1984) A stopped-flow investigation of calcium ion binding by ethylene glycol bis(β-aminoethyl ether)-N,N′-tetraacetic acid. Anal. Biochem. 143, 188–195 [DOI] [PubMed] [Google Scholar]
  • 33. Pidcock E., Moore G. R. (2001) Structural characteristics of protein binding sites for calcium and lanthanide ions. J. Biol. Inorg. Chem. 6, 479–489 [DOI] [PubMed] [Google Scholar]
  • 34. Brahms S., Brahms J. (1980) Determination of protein secondary structure in solution by vacuum ultraviolet circular dichroism. J. Mol. Biol. 138, 149–178 [DOI] [PubMed] [Google Scholar]
  • 35. Morrisett J. D., Broomfield C. A. (1971) Active site spin-labeled -chymotrypsin. Guanidine hydrochloride denaturation studies using electron paramagnetic resonance and circular dichroism. J. Am. Chem. Soc. 93, 7297–7304 [DOI] [PubMed] [Google Scholar]
  • 36. Rigden D. J., Galperin M. Y. (2004) The DxDxDG motif for calcium binding: multiple structural contexts and implications for evolution. J. Mol. Biol. 343, 971–984 [DOI] [PubMed] [Google Scholar]
  • 37. Rigden D. J., Woodhead D. D., Wong P. W., Galperin M. Y. (2011) New structural and functional contexts of the Dx(DN)xDG linear motif: insights into evolution of calcium-binding proteins. PLoS One 6, e21507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Handford P. A., Mayhew M., Baron M., Winship P. R., Campbell I. D., Brownlee G. G. (1991) Key residues involved in calcium-binding motifs in EGF-like domains. Nature 351, 164–167 [DOI] [PubMed] [Google Scholar]
  • 39. Remmert M., Biegert A., Hauser A., Söding J. (2012) HHblits: lightning-fast iterative protein sequence searching by HMM-HMM alignment. Nat. Methods 9, 173–175 [DOI] [PubMed] [Google Scholar]
  • 40. Thompson J., Baker D. (2011) Incorporation of evolutionary information into Rosetta comparative modeling. Proteins 79, 2380–2388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Rajini B., Shridas P., Sundari C. S., Muralidhar D., Chandani S., Thomas F., Sharma Y. (2001) Calcium binding properties of γ-crystallin: calcium ion binds at the Greek key β γ-crystallin fold. J. Biol. Chem. 276, 38464–38471 [DOI] [PubMed] [Google Scholar]
  • 42. Aravind P., Mishra A., Suman S. K., Jobby M. K., Sankaranarayanan R., Sharma Y. (2009) The β γ-crystallin superfamily contains a universal motif for binding calcium. Biochemistry 48, 12180–12190 [DOI] [PubMed] [Google Scholar]
  • 43. Sigrist C. J., Cerutti L., de Castro E., Langendijk-Genevaux P. S., Bulliard V., Bairoch A., Hulo N. (2010) PROSITE, a protein domain database for functional characterization and annotation. Nucleic Acids Res. 38, D161–166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Innis C. A., Shi J., Blundell T. L. (2000) Evolutionary trace analysis of TGF-β and related growth factors: implications for site-directed mutagenesis. Protein Eng. 13, 839–847 [DOI] [PubMed] [Google Scholar]
  • 45. Dudev T., Lim C. (2003) Principles governing Mg, Ca, and Zn binding and selectivity in proteins. Chem. Rev. 103, 773–788 [DOI] [PubMed] [Google Scholar]
  • 46. Maurer P., Hohenadl C., Hohenester E., Göhring W., Timpl R., Engel J. (1995) The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. J. Mol. Biol. 253, 347–357 [DOI] [PubMed] [Google Scholar]
  • 47. Meldolesi J., Pozzan T. (1998) The endoplasmic reticulum Ca2+ store: a view from the lumen. Trends Biochem. Sci. 23, 10–14 [DOI] [PubMed] [Google Scholar]
  • 48. Joe M. K., Sohn S., Choi Y. R., Park H., Kee C. (2005) Identification of flotillin-1 as a protein interacting with myocilin: implications for the pathogenesis of primary open-angle glaucoma. Biochem. Biophys. Res. Commun. 336, 1201–1206 [DOI] [PubMed] [Google Scholar]
  • 49. Hillier B. J., Vacquier V. D. (2003) Amassin, an olfactomedin protein, mediates the massive intercellular adhesion of sea urchin coelomocytes. J. Cell Biol. 160, 597–604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Clapham D. E. (2007) Calcium signaling. Cell 131, 1047–1058 [DOI] [PubMed] [Google Scholar]
  • 51. Tumminia S. J., Mitton K. P., Arora J., Zelenka P., Epstein D. L., Russell P. (1998) Mechanical stretch alters the actin cytoskeletal network and signal transduction in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 39, 1361–1371 [PubMed] [Google Scholar]
  • 52. Tamm E. R., Russell P., Epstein D. L., Johnson D. H., Piatigorsky J. (1999) Modulation of myocilin/TIGR expression in human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 40, 2577–2582 [PubMed] [Google Scholar]
  • 53. Borrás T., Comes N. (2009) Evidence for a calcification process in the trabecular meshwork. Exp. Eye Res. 88, 738–746 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Kennedy K. D., AnithaChristy S. A., Buie L. K., Borrás T. (2012) Cystatin a, a potential common link for mutant myocilin causative glaucoma. PLoS One 7, e36301. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES